Sponsor: Akeso Biopharma
Sponsor Study ID: AK117-205
Study Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study of AK117 or Placebo in Combination with Azacitidine in Patients With Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
CTO #: 104039
NCT Number: NCT06196203
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Hematopoietic
Study Objectives: To evaluate the complete rem1ss1on rate (CRR) of AKl 17 in combination with azacitidine m reference to placebo combined with azacitidine, as assessed by investigator, based on 2023 International Working Group response criteria (IWG 2023).